Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
Background Tenofovir (TFV)-diphosphate (TFV-DP) concentrations in dried blood spots (DBS) demonstrate strong associations with adherence, virologic suppression (VS) and future viremia in persons with HIV (PWH) but data are limited to the older TFV prodrug or PWH with VS on TFV alafenamide (TAF). We examined TFV-DP in DBS and its association with VS at baseline among…
Background ART-free HIV viral control remains an unmet need for people with HIV (PWH). Trosunilimab, an anti-α4β7 integrin antibody with preserved Fc functionality, is expected to induce immune responses to control viral replication, and was evaluated in a phase 1 program in healthy volunteers (HV) and PWH. Methods The double-blind, placebo (PBO) controlled phase 1…
Background TMB-365, a second-generation post-attachment bNAb binds to the second domain of CD4 and displays improved PK, antiviral activity, and breadth of coverage when compared to ibalizumab. TMB-380 (VRC07-523LS) is a bNAb that binds to the CD4 binding site of HIV Env and has potent antiviral activity and favorable safety and PK profile. Here we…
Background To date clinical trials have been underpowered to assess the preferred antiretrovirals in therapy-naïve people with advanced HIV disease (PWAH). We investigated the efficacy and safety of an integrase inhibitor (INI) versus a boosted protease inhibitor (PI) containing regimen in PWAH. Methods In this open-label, randomised, multicentre, non-inferiority trial, therapy-naive people with HIV aged…
Background Currently, optimal timing and/or number of booster COVID19 vaccinations remains unclear. We compared immunogenicity and safety of mRNA booster vaccination at different time intervals. Methods In a randomised, controlled, multicentre, phase II trial, adults with >3 prior mRNA COVID19 vaccines, with last vaccine 3 to 7 months (M) prior, were randomized to one of…
Background Treatment with long-acting antiretroviral therapy (LA ART) with cabotegravir/rilpivirine (CAB/RPV) +/- lenacapavir (LEN) holds promise to achieve viral suppression (VS) in people with HIV (PWH) for whom oral ART fails. Although supported in certain scenarios by guidelines, scaling this approach in viremic PWH has lagged Methods We performed a retrospective review of PWH cared for…
Background The effect of metformin on reducing symptom duration among low-risk, outpatient adults with mild to moderate coronavirus disease 2019 (COVID-19) has not been studied. Our objective was to test metformin compared to placebo for symptom resolution during acute infection with SARS-CoV-2. Methods The ACTIV-6 platform clinical trial evaluated repurposed medications for mild to moderate…
Background Globally there are up to 2.3 million people living with HIV (PLHIV) and hepatitis C virus (HCV) co-infection. PLHIV with HCV co-infection are at high risk for liver-related morbidity and mortality. There are currently no approved direct acting antivirals (DAA) for acute HCV infection; however, glecaprevir/pibrentasvir (G/P) has been well studied in chronic HCV…
Background Background: Point-of-care ultrasound (POCUS) has emerged globally as inexpensive tool used by various healthcare professionals. We evaluated the accuracy of a novel point-of-care liver ultrasound protocol for hepatitis (PUSH) in detecting significant fibrosis, cirrhosis, and suspicious liver lesions in Zambia. Methods Method: we performed a real-world validation of the PUSH at University Teaching hospital in Lusaka, Zambia, from March…
Background Kaposi sarcoma-associated herpesvirus (KSHV) is the etiologic agent of the AIDS-defining cancer Kaposi sarcoma (KS). Despite widespread use of antiretroviral therapy, KSHV seroprevalence remains at 40% in HIV+ individuals in the US. HIV infection promotes KS development via angiogenic and pro-inflammatory factors and KSHV infection drives angiogenesis as observed in highly vascularized KS lesions…